US · SXTC
China SXT Pharmaceuticals, Inc.
- Sector
- Healthcare · Drug Manufacturers - Specialty & Generic
- Headquarters
- Taizhou 225300
- Website
- sxtchina.com
Price · as of 2025-03-31
$2.07
Market cap 1.95M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $148.90 | +7,093.24% |
| Intrinsic Value(DCF) | $133.99 | +6,372.95% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $10.17 | +391.3% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | $655.02 | $3,789.86 | |||
| 2018 | $776.73 | $5,002.95 | |||
| 2019 | $48,450.00 | $130,738.09 | $3,584.31 | $1,828.46 | $1,188.27 |
| 2020 | $6,600.00 | $26,304.81 | $450.85 | $0.00 | $14,246.70 |
| 2021 | $5,925.00 | $107,397.77 | $416.54 | $77.15 | $0.00 |
| 2022 | $6,450.00 | $41,365.19 | $233.30 | $0.00 | $4,894.24 |
| 2023 | $847.50 | $6,515.47 | $29.39 | $0.00 | $333.83 |
| 2024 | $160.50 | $1,187.19 | $12.04 | $0.00 | $0.00 |
| 2025 | $291.00 | $148.90 | $29.30 | $0.00 | $10.17 |
AI valuation
Our deep-learning model estimates China SXT Pharmaceuticals, Inc.'s (SXTC) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $148.90
- Current price
- $2.07
- AI upside
- +7,093.24%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$133.99
+6,372.95% upside
Graham-Dodd
—
— upside
Graham Formula
$10.17
+391.3% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| SXTC | China SXT Pharmaceuticals… | $2.07 | 1.95M | +7,093% | +6,373% | — | +391% | -35.58 | 7.61 | 67.52 | -39.03 | -27.55 | 7.62 | 21.11% | -153.97% | -189.77% | -22.50% | -189.29% | -14.75% | 0.06 | -4.14 | 3.54 | 3.33 | 6.65 | 12913.00% | -973.00% | 2130.00% | -2.00% | -0.39 | -165.76% | 0.00% | 0.00% | 6.54% | -37.47 | -42.78 | 57.69 | 10.04 |
| ATLN | Atlantic International Co… | $3.15 | 223.78M | +816% | -55% | — | — | -0.97 | -10.93 | 0.30 | -1.89 | -0.19 | -3.02 | 10.66% | -4.93% | -30.61% | 527.46% | -25.40% | -108.64% | -6.88 | -1.82 | 0.91 | 0.76 | -0.73 | 51333.00% | 1027.00% | -3383.00% | -4.61% | -0.06 | -7.05% | 0.00% | 0.00% | 45.10% | -9.77 | -35.22 | 0.48 | 1.97 |
| AVR | Anteris Technologies Glob… | $6.51 | 239.49M | +229% | -58% | — | +1,116% | -1.66 | -1678.27 | 81.59 | -1.58 | -27.15 | -987.84 | 70.26% | 24.41% | -4925.51% | -300.71% | -5.60% | -181.73% | -24.54 | 6.40 | 0.73 | 0.59 | 0.11 | 610.00% | -2923.00% | 2251.00% | -49.85% | -3.64 | 932.39% | 0.00% | 0.00% | 0.00% | 312.17 | -1.87 | 76.21 | -18.68 |
| FATE | Fate Therapeutics, Inc. | $1.48 | 170.72M | +1,664% | -45% | — | +3,067% | -1.31 | 0.86 | 26.81 | -0.41 | — | 0.86 | -94.12% | -2222.45% | -2051.08% | -51.84% | -143.19% | -35.89% | 0.38 | — | 5.79 | 5.67 | -0.25 | -2988.00% | -5124.00% | -936.00% | -62.88% | -2.94 | -108.62% | 0.00% | 0.00% | 10.10% | -0.35 | -0.47 | 7.88 | -6.64 |
| IPHA | Innate Pharma S.A. | $1.72 | 160.74M | +2,263% | -50% | — | +2,571% | -2.98 | 16.70 | 11.69 | -2.08 | -0.52 | 16.70 | 100.00% | -408.64% | -391.97% | -162.91% | 247.94% | -34.57% | 3.51 | -91.12 | 2.60 | 2.50 | 0.75 | 57778.00% | -7568.00% | -7913.00% | -4.94% | -0.21 | 35.03% | 0.00% | 0.00% | 3.18% | -1.90 | -13.41 | 7.74 | -4.85 |
| IXHL | Incannex Healthcare Limit… | $4.24 | 48.7M | +3,609% | +49% | — | — | -0.39 | 1.35 | 210.33 | -0.07 | -0.04 | 1.35 | 100.00% | -27661.63% | -54517.44% | -381.09% | -1055.21% | -250.09% | 0.02 | -78.51 | 2.86 | 2.82 | 0.31 | 109298.00% | 37870.00% | -2234.00% | -69.22% | -1.79 | -577.00% | 0.00% | 0.00% | 51.39% | -0.14 | -0.26 | 38.46 | -12.32 |
| MIST | Milestone Pharmaceuticals… | $1.71 | 145.64M | +1,960% | — | — | — | -2.76 | 8.71 | — | -2.63 | — | 8.71 | 0.00% | — | — | -277.55% | -10631.82% | -55.09% | 4.17 | 11.76 | 9.10 | 8.87 | -0.78 | -5180.00% | -10000.00% | -3794.00% | -25.23% | -3.55 | -7293.18% | 0.00% | 0.00% | 7.45% | -2.36 | -3.45 | — | -6.51 |
| NVCT | Nuvectis Pharma, Inc. | $8.86 | 234.72M | — | — | — | — | -7.46 | 10.71 | — | -6.00 | -39.42 | 10.71 | 0.00% | — | — | -188.03% | 250.21% | -105.10% | 0.00 | — | 2.38 | 2.38 | 1.15 | 1892.00% | — | 3072.00% | -8.12% | -1.20 | 145.27% | 0.00% | 0.00% | 6.64% | -6.00 | -10.34 | — | 2.32 |
| SAVA | Cassava Sciences, Inc. | $2.28 | 110.14M | — | — | — | — | -5.35 | 0.89 | — | -0.01 | — | 0.89 | 0.00% | — | — | -17.19% | -845.41% | -15.75% | 0.00 | — | 11.62 | 11.02 | 0.91 | -7759.00% | — | 4196.00% | -89.90% | -9.95 | -699.49% | 0.00% | 0.00% | 5.71% | -0.01 | -0.01 | — | 0.99 |
| TNXP | Tonix Pharmaceuticals Hol… | $13.97 | 178.65M | -2% | -63% | — | — | -0.23 | 0.21 | 2.92 | 0.86 | — | 0.21 | 23.07% | -1354.28% | -1288.25% | -106.12% | -200.34% | -81.95% | 0.04 | — | 6.50 | 5.83 | 1.26 | -9723.00% | 2994.00% | -4445.00% | -207.14% | -3.33 | -89.46% | 0.00% | 0.00% | 265.83% | 0.47 | 1.05 | -6.34 | -7.49 |
About China SXT Pharmaceuticals, Inc.
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, ShaRen, and ChenXiang. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company serves pharmaceutical companies, chain pharmacies, and hospitals, as well as pharmaceutical distributors. China SXT Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Taizhou, China.
- CEO
- Feng Zhou
- Employees
- 75
- Beta
- 1.68
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($133.99 ÷ $2.07) − 1 = +6,372.95% (DCF, example).